Workflow
保本型收益凭证
icon
Search documents
慧翰股份:拟使用不超过5.00亿元闲置募集资金进行现金管理
南财智讯10月9日电,慧翰股份公告,公司第四届董事会第十五次会议于2025年10月9日审议通过了《关 于使用部分闲置募集资金进行现金管理的议案》。公司拟使用不超过5.00亿元暂时闲置募集资金进行现 金管理,资金将用于购买安全性高、流动性好的保本型产品,包括但不限于结构性存款、定期存款、大 额存单、通知存款、保本型收益凭证等,单个产品的投资期限不超过12个月,使用期限自公司董事会审 议通过之日起12个月内有效,资金在额度范围内可滚动使用。此次现金管理不会影响公司募投项目的正 常进行,旨在提高募集资金使用效率,增加现金资产收益。 ...
威高骨科拟用不超23亿元闲置自有资金进行现金管理
Xin Lang Cai Jing· 2025-08-27 17:19
Core Viewpoint - Shandong Weigao Orthopedic Materials Co., Ltd. announced plans to use part of its idle funds for cash management, aiming to enhance fund efficiency and returns while ensuring normal operations and fund safety [1][2]. Cash Management Overview - Investment Purpose: To improve fund efficiency and returns while safeguarding normal operations and fund safety, ultimately benefiting shareholders [2]. - Investment Products: The company plans to invest in high-security, liquid financial products with capital protection agreements, such as principal-protected wealth management products, structured deposits, and fixed-term deposits [2]. - Decision Validity: The resolution is valid for 12 months from the date of board approval, with a maximum investment of RMB 2.3 billion [2]. - Implementation: The board authorizes the chairman and management to make investment decisions within the approved limits and timeframe [2]. - Information Disclosure: The company will comply with legal requirements for timely information disclosure [2]. Risk Management and Control - The company has implemented several risk control measures, including selecting reputable financial institutions, real-time monitoring of product performance, and prohibiting personal account operations [3]. - Internal audits will evaluate investment risks and returns, with oversight from independent directors and the supervisory board [3]. Impact on the Company - The cash management initiative will not affect the company's main business operations or shareholder interests, and is expected to enhance fund efficiency and returns [4]. - Both the board and supervisory board have expressed clear agreement on the cash management plan, deeming it compliant with relevant requirements [4].
耐科装备: 国元证券股份有限公司关于安徽耐科装备科技股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Zheng Quan Zhi Xing· 2025-08-15 11:17
Core Viewpoint - The company intends to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency and returns while ensuring that it does not affect the construction of investment projects or the normal operations of the company [1][10]. Fundraising Basic Situation - The company was approved to publicly issue 20.5 million shares at a price of RMB 37.85 per share, raising a total of RMB 701.33 million, which was fully received by November 2, 2022 [1][2]. Investment Project Situation - The total investment amount for the projects funded by the raised funds is RMB 412.42 million, with the company experiencing temporary idle funds due to the construction cycle of these projects [3][4]. Previous Authorization for Cash Management - The company’s board approved the use of up to RMB 670 million of temporarily idle funds for cash management on December 3, 2022, allowing for investments in high-security, liquid financial products [5][6]. Current Cash Management Usage - The company plans to use up to RMB 500 million of temporarily idle funds for cash management, with a focus on safe and liquid investment products, ensuring that these funds are not used for pledging or securities investment [6][7]. Investment Purpose and Products - The purpose of using idle funds is to improve efficiency and returns without impacting project construction or fund safety. The investment products include guaranteed principal financial products, structured deposits, and large certificates of deposit [6][8]. Investment Limits and Duration - The company will use a maximum of RMB 500 million for cash management, with a validity period of 12 months from the board's approval date, allowing for rolling use of the funds within this limit [6][9]. Impact on Daily Operations - The cash management of idle funds will not affect the ongoing investment projects or the company's main business, and it aims to enhance fund efficiency and returns for shareholders [7][9]. Supervisory and Sponsor Opinions - The supervisory board agrees that the cash management plan complies with relevant regulations and will not harm the interests of shareholders, while the sponsor confirms that the necessary approval procedures have been followed [9][10].
美迪西:关于使用部分暂时闲置募集资金进行现金管理的公告
Zheng Quan Ri Bao· 2025-08-08 16:17
Group 1 - The company, Medisi, announced on August 8 that it will hold the fifth meeting of the fourth board of directors and the fifth meeting of the fourth supervisory board on August 8, 2025 [2] - The company approved a proposal to use part of the temporarily idle raised funds for cash management, with a maximum amount of RMB 400 million [2] - The funds will be used to purchase investment products with high safety and liquidity, including but not limited to guaranteed wealth management products, guaranteed income certificates, structured deposits, time deposits, notice deposits, and large-denomination certificates of deposit [2] - The usage period for these funds is within 12 months from the approval of the board meeting, allowing for rolling use within the specified limit and validity period of the resolution [2]
美迪西: 广发证券股份有限公司关于上海美迪西生物医药股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Zheng Quan Zhi Xing· 2025-08-08 09:20
Summary of Key Points Core Viewpoint - The company, Shanghai Medicy Bio-pharmaceutical Co., Ltd., is utilizing part of its idle raised funds for cash management to enhance fund efficiency and generate additional income while ensuring the safety of the funds and not affecting the ongoing investment projects [1][8]. Group 1: Fundraising Overview - The total amount raised by the company as of August 4, 2023, is RMB 1 billion, with a net amount of RMB 985.29 million after deducting underwriting fees [1]. - The funds are stored in a special account, and a tripartite agreement has been signed to regulate the management of these funds [2]. Group 2: Investment Project Details - The net amount raised will be allocated to specific projects, including the establishment of a biopharmaceutical innovation industrial base and laboratory expansion for drug discovery and pharmaceutical research [2]. - The total planned investment for these projects is RMB 2.176 billion, with the adjusted amount from the raised funds being RMB 216 million [2]. Group 3: Cash Management Strategy - The company plans to use up to RMB 400 million of the temporarily idle funds for cash management, ensuring that this does not impact the ongoing projects [4][7]. - The cash management products will include safe and liquid investments such as principal-protected wealth management products, structured deposits, and time deposits [4][6]. Group 4: Decision-Making and Oversight - The board of directors has authorized the management to make investment decisions within the set limits and timeframes, with the finance department responsible for implementation [4][6]. - The company will adhere to disclosure obligations and ensure that the cash management does not alter the intended use of the raised funds [5][8]. Group 5: Monitoring and Compliance - The supervisory board supports the cash management initiative, stating it aligns with regulations and benefits the company and shareholders [7]. - The sponsor institution has confirmed that the cash management plan complies with relevant regulations and does not affect the normal execution of investment projects [8].